Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Abiraterone and increased survival in metastatic prostate cancer.
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. de Bono JS, et al. Among authors: flechon a. N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618. N Engl J Med. 2011. PMID: 21612468 Free PMC article. Clinical Trial.
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.
de Bono JS, Bellmunt J, Attard G, Droz JP, Miller K, Flechon A, Sternberg C, Parker C, Zugmaier G, Hersberger-Gimenez V, Cockey L, Mason M, Graham J. de Bono JS, et al. Among authors: flechon a. J Clin Oncol. 2007 Jan 20;25(3):257-62. doi: 10.1200/JCO.2006.07.0888. J Clin Oncol. 2007. PMID: 17235043 Clinical Trial.
Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.
Fléchon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis G, Joly F, Oudard S, Deplanque G, Zanetta S, Fargeot P, Priou F, Droz JP, Culine S. Fléchon A, et al. Ann Oncol. 2011 Nov;22(11):2476-2481. doi: 10.1093/annonc/mdr004. Epub 2011 Mar 24. Ann Oncol. 2011. PMID: 21436186 Free article. Clinical Trial.
2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial.
Bachner M, Loriot Y, Gross-Goupil M, Zucali PA, Horwich A, Germa-Lluch JR, Kollmannsberger C, Stoiber F, Fléchon A, Oechsle K, Gillessen S, Oldenburg J, Cohn-Cedermark G, Daugaard G, Morelli F, Sella A, Harland S, Kerst M, Gampe J, Dittrich C, Fizazi K, De Santis M. Bachner M, et al. Among authors: flechon a. Ann Oncol. 2012 Jan;23(1):59-64. doi: 10.1093/annonc/mdr052. Epub 2011 Apr 2. Ann Oncol. 2012. PMID: 21460378 Free article.
[High dose chemotherapy and germ cell tumor].
Massard C, Fléchon A, Fizazi K, Droz JP. Massard C, et al. Among authors: flechon a. Bull Cancer. 2011 Aug;98(8):945-9. doi: 10.1684/bdc.2011.1406. Bull Cancer. 2011. PMID: 21821481 Free article. Review. French.
Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01).
Culine S, Fléchon A, Guillot A, Le Moulec S, Pouessel D, Rolland F, Ravaud A, Houédé N, Mignot L, Joly F, Oudard S, Gourgou S. Culine S, et al. Among authors: flechon a. Eur Urol. 2011 Dec;60(6):1251-7. doi: 10.1016/j.eururo.2011.08.072. Epub 2011 Sep 10. Eur Urol. 2011. PMID: 21924547 Clinical Trial.
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.
Fizazi K, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houedé N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Lagrange JL, Chinet-Charrot P, Linassier C, Deplanque G, Beuzeboc P, Geneve J, Davin JL, Tournay E, Culine S. Fizazi K, et al. Among authors: flechon a. Eur J Cancer. 2012 Jan;48(2):209-17. doi: 10.1016/j.ejca.2011.10.015. Epub 2011 Nov 24. Eur J Cancer. 2012. PMID: 22119204 Clinical Trial.
Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Fizazi K, De Bono JS, Flechon A, Heidenreich A, Voog E, Davis NB, Qi M, Bandekar R, Vermeulen JT, Cornfeld M, Hudes GR. Fizazi K, et al. Among authors: flechon a. Eur J Cancer. 2012 Jan;48(1):85-93. doi: 10.1016/j.ejca.2011.10.014. Epub 2011 Nov 28. Eur J Cancer. 2012. PMID: 22129890 Clinical Trial.
Increased survival with enzalutamide in prostate cancer after chemotherapy.
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators. Scher HI, et al. Among authors: flechon a. N Engl J Med. 2012 Sep 27;367(13):1187-97. doi: 10.1056/NEJMoa1207506. Epub 2012 Aug 15. N Engl J Med. 2012. PMID: 22894553 Free article. Clinical Trial.
234 results